Source:http://linkedlifedata.com/resource/pubmed/id/18798551
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
12
|
| pubmed:dateCreated |
2008-12-16
|
| pubmed:abstractText |
In mantle cell lymphoma (MCL), minimal residual disease (MRD) is an indicator of the disease outcome. Quantitative methods used so far do not provide a suitable molecular marker in 30-70% patients with MCL (depending on the technique used). We tested cyclin D1 as a marker for quantitative MRD monitoring. The real-time PCR of cyclin D1 mRNA was performed in 144 bone marrow (BM) specimens including 95 BMs from MCL patients, 39 BMs from patients with other B-cell non-Hodgkin's lymphomas and 10 BMs from healthy volunteer donors. In 73 BMs obtained from 20 MCL patients we examined the cyclin D1 level during the treatment and follow-up period. We detected a cyclin D1 overexpression exclusively in BMs infiltrated with MCL, including minimal residual infiltration. Dynamics of cyclin D1 correlated with the patient's clinical status in 69/73 BMs. Individual monitoring of patients during the disease course showed cyclin D1 quantitative changes accompanying either the disease relapse or a successful treatment response or the disease-free survival (remission) and it showed a predictive significance. Cyclin D1 detection is a promising approach for the quantitative MRD monitoring in MCL patients, and the individual monitoring of the cyclin D1 dynamics represents a suitable indicator of the disease course.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
1097-0215
|
| pubmed:author | |
| pubmed:copyrightInfo |
(c) 2008 Wiley-Liss, Inc.
|
| pubmed:issnType |
Electronic
|
| pubmed:day |
15
|
| pubmed:volume |
123
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
2865-70
|
| pubmed:meshHeading |
pubmed-meshheading:18798551-Adult,
pubmed-meshheading:18798551-Aged,
pubmed-meshheading:18798551-Bone Marrow,
pubmed-meshheading:18798551-Case-Control Studies,
pubmed-meshheading:18798551-Cyclin D1,
pubmed-meshheading:18798551-Disease-Free Survival,
pubmed-meshheading:18798551-Female,
pubmed-meshheading:18798551-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:18798551-Humans,
pubmed-meshheading:18798551-Lymphoma, Mantle-Cell,
pubmed-meshheading:18798551-Male,
pubmed-meshheading:18798551-Middle Aged,
pubmed-meshheading:18798551-Neoplasm, Residual,
pubmed-meshheading:18798551-Polymerase Chain Reaction,
pubmed-meshheading:18798551-Predictive Value of Tests,
pubmed-meshheading:18798551-Prognosis,
pubmed-meshheading:18798551-RNA, Messenger,
pubmed-meshheading:18798551-Sensitivity and Specificity,
pubmed-meshheading:18798551-Tumor Markers, Biological
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
Quantitative monitoring of cyclin D1 expression: a molecular marker for minimal residual disease monitoring and a predictor of the disease outcome in patients with mantle cell lymphoma.
|
| pubmed:affiliation |
Department of Pathology and Molecular Medicine, 2nd Medical School, Charles University in Prague, and Faculty Hospital in Motol, Prague, Czech Republic. helena.brizova@fnmotol.cz
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|